ZLTQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZLTQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ZELTIQ Aesthetics's Earnings per Share (Diluted) for the three months ended in Dec. 2016 was $0.26. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 was $0.01.
ZELTIQ Aesthetics's EPS (Basic) for the three months ended in Dec. 2016 was $0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2016 was $0.02.
ZELTIQ Aesthetics's EPS without NRI for the three months ended in Dec. 2016 was $0.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2016 was $0.01.
The historical data trend for ZELTIQ Aesthetics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZELTIQ Aesthetics Annual Data | |||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -0.87 | -0.53 | 0.04 | 1.02 | 0.02 |
ZELTIQ Aesthetics Quarterly Data | ||||||||||||||||||||
Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | 0.99 | -0.25 | -0.12 | 0.12 | 0.26 |
For the Medical Devices subindustry, ZELTIQ Aesthetics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, ZELTIQ Aesthetics's PE Ratio distribution charts can be found below:
* The bar in red indicates where ZELTIQ Aesthetics's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
ZELTIQ Aesthetics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2016 is calculated as
Diluted Earnings Per Share (A: Dec. 2016 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (0.694 | - | 0) | / | 41.461 | |
= | 0.02 |
ZELTIQ Aesthetics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2016 is calculated as
Diluted Earnings Per Share (Q: Dec. 2016 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (10.277 | - | 0) | / | 41.461 | |
= | 0.25 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
ZELTIQ Aesthetics (NAS:ZLTQ) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of ZELTIQ Aesthetics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Todd Erik Zavodnick | officer: President, International | C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560 |
Bradley Hauser | officer: SVP, Research and Development | C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
Danika R Harrison | officer: SVP of Global Marketing | C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588 |
Mark J Foley | director, officer: President and CEO | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Taylor C. Harris | officer: SVP & Chief Financial Officer | 6035 STONERIDGE DRIVE, PLEASANTON CA 94588 |
Kevin C Oboyle | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Mary Fisher | director | C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
D Keith Grossman | director | |
Andrew N Schiff | director, 10 percent owner | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Keith J Sullivan | officer: CCO, President, North America | C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043 |
Patrick F. Williams | officer: SVP & CFO | C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
Leonard C Debenedictis | officer: Chief Technical Officer | C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043 |
Bryan E Roberts | director | C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025 |
Jean George | director | CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421 |
Aisling Capital Iii Lp | 10 percent owner | 888 Seventh Avenue, 30th Fl, New York NY 10106 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.